CLDX
Price
$22.92
Change
-$1.40 (-5.76%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
1.52B
48 days until earnings call
SNDX
Price
$12.60
Change
-$0.20 (-1.56%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
1.08B
50 days until earnings call
Ad is loading...

CLDX vs SNDX

Header iconCLDX vs SNDX Comparison
Open Charts CLDX vs SNDXBanner chart's image
Celldex Therapeutics
Price$22.92
Change-$1.40 (-5.76%)
Volume$35.28K
Capitalization1.52B
Syndax Pharmaceuticals
Price$12.60
Change-$0.20 (-1.56%)
Volume$293.32K
Capitalization1.08B
CLDX vs SNDX Comparison Chart
Loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLDX vs. SNDX commentary
Jan 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and SNDX is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 15, 2025
Stock price -- (CLDX: $22.94 vs. SNDX: $12.60)
Brand notoriety: CLDX and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 134% vs. SNDX: 81%
Market capitalization -- CLDX: $1.52B vs. SNDX: $1.08B
CLDX [@Biotechnology] is valued at $1.52B. SNDX’s [@Biotechnology] market capitalization is $1.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $374.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, CLDX is a better buy in the long-term than SNDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 4 TA indicator(s) are bullish while SNDX’s TA Score has 4 bullish TA indicator(s).

  • CLDX’s TA Score: 4 bullish, 3 bearish.
  • SNDX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both CLDX and SNDX are a good buy in the short-term.

Price Growth

CLDX (@Biotechnology) experienced а -16.88% price change this week, while SNDX (@Biotechnology) price change was -8.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.85%. For the same industry, the average monthly price growth was -2.06%, and the average quarterly price growth was -3.70%.

Reported Earning Dates

CLDX is expected to report earnings on May 13, 2025.

SNDX is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-6.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.52B) has a higher market cap than SNDX($1.08B). SNDX YTD gains are higher at: -3.177 vs. CLDX (-3.759). CLDX has higher annual earnings (EBITDA): -171.06M vs. SNDX (-296.86M). CLDX has more cash in the bank: 756M vs. SNDX (406M). SNDX has less debt than CLDX: SNDX (854K) vs CLDX (3.09M). SNDX has higher revenues than CLDX: SNDX (16M) vs CLDX (9.98M).
CLDXSNDXCLDX / SNDX
Capitalization1.52B1.08B141%
EBITDA-171.06M-296.86M58%
Gain YTD-3.759-3.177118%
P/E RatioN/AN/A-
Revenue9.98M16M62%
Total Cash756M406M186%
Total Debt3.09M854K361%
FUNDAMENTALS RATINGS
CLDX vs SNDX: Fundamental Ratings
CLDX
SNDX
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
4670
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
8890
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (57) in the Biotechnology industry is in the same range as SNDX (84). This means that CLDX’s stock grew similarly to SNDX’s over the last 12 months.

CLDX's Profit vs Risk Rating (46) in the Biotechnology industry is in the same range as SNDX (70). This means that CLDX’s stock grew similarly to SNDX’s over the last 12 months.

CLDX's SMR Rating (96) in the Biotechnology industry is in the same range as SNDX (98). This means that CLDX’s stock grew similarly to SNDX’s over the last 12 months.

CLDX's Price Growth Rating (88) in the Biotechnology industry is in the same range as SNDX (90). This means that CLDX’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for CLDX (100). This means that SNDX’s stock grew significantly faster than CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXSNDX
RSI
ODDS (%)
N/A
Bullish Trend 7 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
75%
Bearish Trend 7 days ago
79%
Momentum
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 7 days ago
86%
MACD
ODDS (%)
Bullish Trend 7 days ago
85%
Bullish Trend 7 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 7 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
81%
Bearish Trend 7 days ago
81%
Advances
ODDS (%)
Bullish Trend 12 days ago
83%
Bullish Trend 7 days ago
82%
Declines
ODDS (%)
Bearish Trend 16 days ago
79%
Bearish Trend 16 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
90%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 7 days ago
75%
View a ticker or compare two or three
Ad is loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRUGX15.000.11
+0.74%
MFS Blended Research Value Equity C
BIRKX21.160.03
+0.14%
BlackRock Sustainable Adg Lg Cp Cr K
LPFCX5.40N/A
N/A
ALPS Global Opportunity C
GEMUX22.84N/A
N/A
Goldman Sachs Emerging Markets Eq R6
JFRNX57.09-0.17
-0.30%
Janus Henderson Forty N

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with KRYS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
-0.12%
KRYS - CLDX
56%
Loosely correlated
-1.71%
ALT - CLDX
45%
Loosely correlated
-1.31%
AXON - CLDX
43%
Loosely correlated
-0.23%
BEAM - CLDX
42%
Loosely correlated
-3.22%
KYMR - CLDX
41%
Loosely correlated
-2.49%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with ABOS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
-2.36%
ABOS - SNDX
46%
Loosely correlated
-3.64%
ARVN - SNDX
46%
Loosely correlated
-3.28%
RAPT - SNDX
45%
Loosely correlated
-8.33%
VCYT - SNDX
45%
Loosely correlated
+2.99%
KYMR - SNDX
44%
Loosely correlated
-2.49%
More